Drug intelligence / Profile preview

ciprofloxacin + ornidazole

Development stage
Phase 3
Modality
Small Molecules
Administration
Oral
01

Overview

Ciprofloxacin + ornidazole is a fixed-dose combination of two antimicrobial agents used to treat a broad range of bacterial and protozoal infections, particularly those involving the gastrointestinal tract, urinary tract, respiratory system, and gynecological or pelvic regions. Ciprofloxacin is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and leading to bacterial cell death. Ornidazole is an antiprotozoal and antibacterial agent from the nitroimidazole class; it works by damaging the DNA of anaerobic bacteria and protozoa, resulting in their death. This combination provides synergistic coverage against both aerobic bacteria (via ciprofloxacin) and anaerobic bacteria/protozoa (via ornidazole), making it effective for mixed infections such as diarrhea (including amoebic dysentery), gynecological infections, dental infections, intra-abdominal infections, giardiasis, amoebiasis, cystitis after urological procedures in women with urinary incontinence surgery history[1][3][4][5][7].

Brand names
Cifran-OZCiplox-OZZoxan OZCiprogyl ForteOsmoflox OZCiporniFloxip OZOrnicipOxigen-GAdflox OZCIP-OCIPOOCIMIX
Other names
ciprofloxacin with ornidazole
02

Targets

DNADNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on ciprofloxacin + ornidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + ornidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call